Disposition of quercetin in man after single oral and intravenous doses.
about
Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development StrategyGastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylationQuercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humansFlavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and GlucoseLipid-based nanocarrier for quercetin delivery: system characterization and molecular interactions studies.Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin/quercetin complex.Methylation of dietary flavones increases their metabolic stability and chemopreventive effectsLow concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.Quantification of the flavonoid-degrading bacterium Eubacterium ramulus in human fecal samples with a species-specific oligonucleotide hybridization probe.Bioavailability of flavonoids and potential bioactive forms in vivo.Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones.The reduction of azo dyes by the intestinal microflora.Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cellsQuercetin conjugated poly(β-amino esters) nanogels for the treatment of cellular oxidative stress.Fecalase: a model for activation of dietary glycosides to mutagens by intestinal flora.Potential mutagenic activity of some vitamin preparations in the human gut.Pharmacokinetic data. Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses.Development and characterization of self-assembling lecithin-based mixed polymeric micelles containing quercetin in cancer treatment and an in vivo pharmacokinetic study.Natural polyphenol disposition via coupled metabolic pathways.Antioxidant activity of phenolic compounds: from in vitro results to in vivo evidence.Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression.Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activityPolyphenols as key players for the antileukaemic effects of propolis.Prooxidant activity of fisetin: effects on energy metabolism in the rat liver.Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53.Natural polyphenols in cancer therapy.Updated knowledge about polyphenols: functions, bioavailability, metabolism, and health.Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women.Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma.Differential impact of flavonoids on redox modulation, bioenergetics and cell signalling in normal and tumor cells: a comprehensive review.Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling.Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.Quercetin Glucoside Production by Engineered Escherichia coli.Inhibitory effect of flavonoids on the efflux of N-acetyl 5-aminosalicylic acid intracellularly formed in Caco-2 cells.Intra-herb pharmacokinetics interaction between quercetin and isorhamentin.Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin.Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake.Functional food science and defence against reactive oxidative species.Potent interaction of flavopiridol with MRP1LC-ESI-MS/MS analysis of quercetin in rat plasma after oral administration of biodegradable nanoparticles.
P2860
Q28076840-9D9AEE94-7D7F-40BD-88D0-D5ED806F5D9EQ28168471-D9610840-510F-4156-86DA-1259ABA981F9Q28481712-E2061969-3EDD-46E3-B023-E0EB721AAC8DQ28578597-F05A52CB-1925-4630-B7A2-4441EB6BE1E4Q31023863-00EB4DE4-AA09-460C-B824-D396B856E48AQ33465236-95F8E99D-3E11-4CDB-9778-CF3C18A6B741Q33596822-BCD3179B-C856-4F2F-BA5F-69430081EA76Q33856711-EA3F8EAB-387F-4806-990B-CD97363C456EQ33985681-6CB8A780-6484-4CF3-ACDF-4DBE85773BB5Q34153254-CEF9DD90-5B63-43ED-ABAA-7B0B271AE1F6Q35793163-1C8A1B60-D506-42D2-B226-C8F324EA1381Q35949832-7151B7F2-D771-495E-A2D4-B384AFA8AA0AQ35982257-70F58F67-F7AB-41DB-96C9-9192D2B4803AQ36173800-E365FA37-BB18-4B41-B02B-93075EDEB104Q36403745-A1380D75-F89A-4B1B-9523-CAAE2E464D82Q36703498-053F8258-824C-45FD-9920-3B9EA03302EDQ36794421-872CCC77-C081-4074-B2FF-F11C82B52543Q36826807-B7A6372B-1DCC-46D8-A8CB-0DF5DF8E6C1EQ36835822-C53B2D67-4999-4030-8130-5961B1A79426Q37229295-AC7F313D-A201-4EBB-8B67-AF728DABCAACQ37330137-C0E56C0F-1D7C-4426-A7FD-F749F0C6B9DEQ37355419-93BBBA59-315E-4FC9-9382-1315E95B3552Q37688081-A7F2DACB-26FF-4316-8B11-647527B8D11BQ37801355-211DC502-C75D-4020-A2BF-1DC26A187E26Q37825339-22F09524-449F-4B09-8CD0-DB207DD8809FQ37964733-A8EFF039-7353-4CE4-8547-0AC9436C6E06Q38022685-119229C6-62DC-4ECD-8352-CE38657578E8Q38526026-410355A9-167D-4B98-A812-9F168DCD556AQ38528842-B8C7510F-C0BA-4F24-A3E0-5F16E22DEB47Q38616035-8B977AB1-28CE-4554-9D3F-3FFF6D8FDCF0Q38712959-5B869D12-1F94-4062-8A66-DF76F87E80D8Q38875292-0300A09C-2595-4FAD-A082-B66166666F45Q39094842-19C91FCE-B17B-4175-97EE-6EEFF3391DDAQ39811425-A425D46A-56AA-4A81-9C1C-D83491C61AEFQ39924679-338AF02B-F23F-43D1-A991-C15A440EB4BBQ40406600-45197168-D514-4D0A-96F1-492064B2D536Q40626528-CA7E290D-0C13-41A6-83EA-2264B756271FQ40832209-50DC43E0-337F-471E-9B7E-16AD0F8EF04DQ40927437-0170F674-F733-4AF3-ACCE-5C97B6AACD57Q40940792-E4A36B66-DB52-4D2C-AFF9-4C0BA53B4059
P2860
Disposition of quercetin in man after single oral and intravenous doses.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
1975年论文
@zh
1975年论文
@zh-cn
name
Disposition of quercetin in man after single oral and intravenous doses.
@en
Disposition of quercetin in man after single oral and intravenous doses.
@nl
type
label
Disposition of quercetin in man after single oral and intravenous doses.
@en
Disposition of quercetin in man after single oral and intravenous doses.
@nl
prefLabel
Disposition of quercetin in man after single oral and intravenous doses.
@en
Disposition of quercetin in man after single oral and intravenous doses.
@nl
P2093
P356
P1476
Disposition of quercetin in man after single oral and intravenous doses.
@en
P2093
P2888
P304
P356
10.1007/BF00614022
P577
1975-12-01T00:00:00Z